Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial.

Abstract Video & Slides Poster

Authors

null

Tycel Jovelle Phillips

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Tycel Jovelle Phillips , Michael Wang , Tadeusz Robak , David Gallinson , Don A. Stevens , Krish Patel , Safaa Ramadan , Chuan-Chuan Wun , Wojciech Jurczak , Stephen Douglas Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02717624

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7546)

DOI

10.1200/JCO.2023.41.16_suppl.7546

Abstract #

7546

Poster Bd #

97

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

Ipatasertib in patients with <em>AKT1/2/3</em> mutation-positive (<em>AKT</em>mut) tumors: TAPISTRY study.

Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.

First Author: David Morgan Thomas

First Author: Nirav Niranjan Shah

First Author: Jeff Porter Sharman

Poster

2021 ASCO Annual Meeting

Capmatinib in <em>MET</em> exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

First Author: Juergen Wolf